Versant Venture Capital VI, L.P. has demonstrated a consistent selling bias across its recent transactions, with no recorded purchases in its SEC Form 4 filings. The firm has executed 38 trades totaling over $52.9 million in sales, with 25 of those occurring in recent months. Its activity has been concentrated in two biotech holdings: LENZ Therapeutics (LENZ) and LAVA Therapeutics (LVTX). The most notable disposals took place on September 30, 2025, when Versant sold LENZ shares across multiple transactions, including a $3.85 million block and another worth $2.67 million. Earlier in September, the firm also offloaded LVTX shares, including a $3.32 million sale on September 19 and smaller dispositions ranging from $294,823 to $746,764 in mid-September.
The pattern suggests an ongoing divestment strategy, particularly in LENZ, where sales have occurred steadily since late August 2025. On August 25–26, Versant sold LENZ shares in increments up to $1.71 million, followed by additional disposals in September, including a $2.25 million transaction on September 30. The absence of buy orders and the scale of these sales indicate a reduction in exposure to these positions, though the filings do not specify whether the sales represent full exits or partial stake adjustments. The transactions were executed at varying price points, reflecting either planned distribution or responsive trading to market conditions.
AI-assisted summary